OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

REGISTERED COMPANY NUMBER: 08082786 (England and Wales) REGISTERED CHARITY NUMBER: 1150234

REPORT OF THE TRUSTEES AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

BRITISH NUCLEAR MEDICINE SOCIETY

E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF

BRITISH NUCLEAR MEDICINE SOCIETY

CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

Page
Report of the Trustees 1 to 5
Independent Examiner's Report 6
Statement of Financial Activities 7
Balance Sheet 8
Cash Flow Statement 9
Notes to the Cash Flow Statement 10
Notes to the Financial Statements 11 to 16
Detailed Statement of Financial Activities 17 to 18

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 December 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES

Objectives and aims

British Nuclear Medicine Society is dedicated to raising the profile of nuclear medicine and to promote the multidisciplinary practice of high quality nuclear medicine for the benefit of patients.

Significant activities

In order for the charity to achieve its aim BNMS engages in the following activities:

Public benefit

The public benefits from the activities of the British Nuclear Medicine Society through the pursuit of its specific objectives including the development and promotion of standards and guidelines for the safe and effective practice of nuclear medicine, the promotion of nuclear medicine research and development and the provision of greater information for the public on the BNMS website.

Page 1

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025

OBJECTIVES AND ACTIVITIES Our committees

Professional Standards Committee

The Professional Standards Committee advises the Officers and Council of BNMS on the development and implementation of professional standards and audit. They develop, promote, publicise and review guidelines for the delivery of nuclear medicine services and procedures and are also responsible for developing patient information in nuclear medicine.

Scientific and Education Committee

The British Nuclear Medicine Society (BNMS) established the combined Scientific Committee and Education Committee in 2016.

The mandate of the Scientific and Education Committee is to develop an education and scientific programme, nominate invited speakers and the chairs of sessions.

The remit of this committee is to provide resources and encourage the provision of education and training to support Continuing Professional Development/Continuous Medical Education and work towards revalidation. The Education Committee is Multidisciplinary, consisting of Nuclear Medicine Physicians, Clinical Practicer's, Physicists, Nurses and Radiopharmacists.

Research & Innovation Committee

Research & Innovation Committee (RIC) reports to BNMS council and governs BNMS Research Champions network and links to the MRT Research Committee.

The purpose of the RIC is to provide integrated clinical, scientific and operational leadership and management/oversight of delivery of the BNMS Research Strategy.

The roles of the Research & Innovation Committee are to develop and deliver BNMS Research Strategy with aims:

  1. To enhance radionuclide research delivery in the United Kingdom leading to service improvement and better care of patients. To accomplish this the BNMS will outline research priority areas highlighting current unmet needs. It will investigate through research sessions and workshops on-line and at face-to-face meetings on how best its multi professional membership can develop projects and achieve funding from the appropriate bodies. The BNMS will facilitate research networks through the BNMS website and offer peer support and review through face-to-face meetings at the BNMS conferences. It will endeavour to contribute to and work with the professional bodies involved in research, the UK Colleges, the charities, and the national and international Nuclear Medicine societies. It will foster links with research partners including the UK PET Network the CRUK Radiation Network, RadNet, the National Cancer Imaging Translational Accelerator (NCITA) and Industry Academic partnership via Industry forum held 2-3 times a year.

  2. To build up an evidence base for new radionuclide molecular diagnostic and therapeutic procedures. The BNMS research network group is developing a database of current research in the UK and a data base of available research funding. It is also developing a database to ethically collect data from ongoing research studies.

UK MRT Consortium

The UK molecular radiotherapy consortium is a group comprised of both healthcare professionals and patient advocates who are directly and passionately associated in delivering and caring for patients undergoing molecular radiotherapy based treatments.

The UK MRT Consortium are the first organisation to serve current and future patients who may find the need to receive such types of treatment to help maintain and sustain both quality and duration of life.

By bringing members and fellows of both the British Nuclear Medicine Society and the Royal College of Radiologists together along with patient advocates and nationally recognised charities, we will endeavour to ensure that all parts of the United Kingdom will have equitable access to current and future therapies, raise public awareness of such treatments, design and encourage activity in nationally recognised molecular radiotherapy trials.

Trainee Committee

Aims of BNMS Medical Trainee Committee

Increase awareness of diagnostic and therapeutic Nuclear Medicine amongst doctors-in-training and medical students.

Provide educational content for doctors-in-training and medical students to aid their understanding of working in Nuclear Medicine and the training pathways.

Page 2

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025

OBJECTIVES AND ACTIVITIES

Provide opportunities for doctors-in-training and medical students to engage with the BNMS and improve their application for the specialities/training numbers.

Radiographers Technologists and Nurses

The BNMS Radiographers, Technologists & Nurses' Committee:-

Objectives

ACHIEVEMENTS AND PERFORMANCE

Charitable activities

The British Nuclear Medicine Society held two scientific and educational meetings this year around the UK in addition to online meetings, the results of which are as follows:

Spring Autumn Online Other
2025 2025 Educational Online Mtgs Total
£ £ £ £ £
Income
Commercial exhibition income 225,002 29,355 0 1,750 256,107
Annual conference delegate registration fees 150,376 22,912 12,950 4,403 190,641
375,378 52,267 12,950 6,153 446,747
Less: Scientific meeting expenses 261,263 66,959 4,654 2,365 335,235
Surplus 114,115 -14,693 8,296 3,788 111,506

Fundraising activities

The British Nuclear Medicine Society generates income from membership fees, from royalties received through "Nuclear Medicine Communications" (the scientific journal of the BNMS) as well registration and exhibitor fees from those attendees at the annual and educational meetings of the Society.

FINANCIAL REVIEW

Reserves policy

The trustees aim to maintain free reserves at a level equivalent to at least 18 months of normal operating expenditure in order to protect the continuity of the charity’s activities and provide cover against volatility in conference and event income.

At 31 December 2025, total funds were £517,041 (2024: £479,992), including restricted funds of £14,642 (2024: £14,480), which are not freely available for general purposes.

Unrestricted funds totalled £502,399 (2024: £465,512), of which £2,958 (2024: £1,644) was represented by tangible fixed assets. On that basis, funds freely available for general purposes were approximately £499,441 (2024: £478,348) before taking account of any internal designations.

The trustees consider this level of reserves to be above the minimum target and appropriate in light of the charity’s reliance on event-generated income and the need to support future charitable activities

FUTURE PLANS

The society will continue to promote the multidisciplinary practice of nuclear medicine for the benefit of patients. It plans to continue holding regular meetings throughout the country and will further encourage regional networks.

Page 3

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, its' articles of association, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

Charity constitution

The affairs of the Society will be governed by a Council of Trustees who will be the officers of the Society and elected members of Council during their period of office.

The Council shall have control of the Society and its property and funds.

Recruitment and appointment of new trustees

New Trustees are elected by the Members or co-opted by the Trustees.

The board of trustees shall be individuals over the age of 18, all of whom must support the Objects, and of whom at least three shall be registered medical practitioners, two shall be clinical scientists, one shall be a radiopharmacist, and one shall be a technologist or radiographer (clinical paractitioner).

The Council shall ensure that at least one medical position is held by a trainee in the speciality, but if such person whilst on Council is appointed to a consultant position, they shall be eligible to complete their term on Council.

Decision making

Every Trustee has one vote on each issue but, in case of equality of votes, the chairman of the meeting has a second or casting vote.

The Trustees have the following powers in the administration of the Society in their capacity as Trustees:

To appoint (and remove) any person (who may be a Trustee) to act as Secretary in accordance with the Companies Act.

To delegate any of their functions to committees consisting of two or more individuals appointed by them. At least one member of every committee must be a Trustee and all proceedings of committees must be reported promptly to the Trustees.

To make standing orders consistent with the Memorandum, the Articles and the Companies Act to govern proceedings at general meetings.

To make rules consistent with the Memorandum, the Articles and the Companies Act to govern their proceedings and proceedings of committees.

To make regulations consistent with the Memorandum, the Articles and the Companies Act to govern the administration of the Society and the use of its seal (if any).

To establish procedures to assist the resolution of disputes or differences within the Society.

To exercise in their capacity as Trustees any powers of the Society which are not reserved to the Members.

Risk management

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

REFERENCE AND ADMINISTRATIVE DETAILS Registered Company number

08082786 (England and Wales)

Registered Charity number

1150234

Registered office

Royal College of Physicians 11 St Andrews Place Regents Park London NW1 4LE

Page 4

BRITISH NUCLEAR MEDICINE SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 31 DECEMBER 2025

Trustees

Who are also directors Mrs J Croasdale (resigned 21 April 2026) Dr S Redman (appointed 20 April 2026) Mr C S Kalirai Mrs S Dizdarevic Dr E A Eccles (appointed 21 May 2025)

Radiopharmacist Radiologist Clinical Scientist Professor Doctor

Independent Examiner

E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF

Approved by order of the board of trustees on 24 July 2026 and signed on its behalf by:

Mr C S Kalirai - Trustee

Page 5

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF BRITISH NUCLEAR MEDICINE SOCIETY

Independent examiner's report to the trustees of British Nuclear Medicine Society ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Since your charity's gross income exceeded £250,000 your examiner must be a member of a listed body. I can confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants in England and Wales, which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

  1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or 2. the accounts do not accord with those records; or

  2. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or

  3. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Steven Lomas

E R Grove & Co Limited Grove House Coombs Wood Court Steel Park Road Halesowen West Midlands B62 8BF

24 July 2026

Page 6

BRITISH NUCLEAR MEDICINE SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2025

Unrestricted
Restricted
fund
fund
Notes
£
£
INCOME AND ENDOWMENTS FROM
Other trading activities
2
524,282
-
Investment income
3
8,046
162
Other income
92,016
-
Total
624,344
162
EXPENDITURE ON
Raising funds
4
587,412
-
NET INCOME/(EXPENDITURE)
36,932
162
RECONCILIATION OF FUNDS
Total funds brought forward
465,512
14,480
TOTAL FUNDS CARRIED FORWARD
502,444
14,642		 2025
Total
funds
£
524,282
8,208
92,016
624,506
587,412
37,094
479,992
517,086		 2024
Total
funds
£
441,142
9,621
75,454
526,217
542,381
(16,164)
496,156
479,992

The notes form part of these financial statements

Page 7

BRITISH NUCLEAR MEDICINE SOCIETY

BALANCE SHEET 31 DECEMBER 2025

Unrestricted
Restricted
fund
fund
Notes
£
£
FIXED ASSETS
Tangible assets
10
2,958
-
CURRENT ASSETS
Debtors
11
283,339
-
Cash at bank
421,366
14,642
704,705
14,642
CREDITORS
Amounts falling due within one year
12
(205,219)
-
NET CURRENT ASSETS
499,486
14,642
TOTAL ASSETS LESS CURRENT LIABILITIES
502,444
14,642
NET ASSETS
502,444
14,642
FUNDS
13
Unrestricted funds
Restricted funds
TOTAL FUNDS		 2025
Total
funds
£
2,958
283,339
436,008
719,347
(205,219)
514,128
517,086
517,086
502,444
14,642
517,086		 2024
Total
funds
£
1,644
243,023
420,001
663,024
(184,676)
478,348
479,992
479,992
465,512
14,480
479,992

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees and authorised for issue on 24 July 2026 and were signed on its behalf by:

Mr C S Kalirai - Trustee

The notes form part of these financial statements

Page 8

BRITISH NUCLEAR MEDICINE SOCIETY

CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

Notes
Cash flows from operating activities
Cash generated from operations
1
Net cash provided by/(used in) operating activities
Cash flows from investing activities
Purchase of tangible fixed assets
Interest received
Net cash provided by investing activities
Change in cash and cash equivalents in
the reporting period
Cash and cash equivalents at the
beginning of the reporting period
Cash and cash equivalents at the end of
the reporting period		 2025
£
9,914
9,914
(2,115)
8,208
6,093
16,007
420,001
436,008		 2024
£
(22,766)
(22,766)
1
9,621
9,622
(13,144)
433,145
420,001

The notes form part of these financial statements

Page 9

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

1. RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASH FLOW FROM OPERATING ACTIVITIES
2025 2024
£ £
Net income/(expenditure) for the reporting period (as per the
Statement of Financial Activities) 37,094 (16,164)
Adjustments for:
Depreciation charges 801 770
Interest received (8,208) (9,621)
Increase in debtors (40,316) (74,498)
Increase in creditors 20,543 76,747
Net cash provided by/(used in) operations 9,914 (22,766)

2. ANALYSIS OF CHANGES IN NET FUNDS

At 1.1.25 Cash flow At 31.12.25
£ £ £
Net cash
Cash at bank 420,001 16,007 436,008
420,001 16,007 436,008
Total 420,001 16,007 436,008

The notes form part of these financial statements

Page 10

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Exhibition income is recognised in the Statement of Financial Activities in the year that the exhibition is held.

Grants and donations are only recognised in the statement of Financial Activity when the charity has unconditional entitlement to the resources. Where the donor imposes conditions that the resource is expended in a future accounting period, income is recorded as deferred income at the balance sheet date and a creditor is included under deferred income.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Exhibition expenses are recognised in the Statement of Financial Activities in the year that the exhibition is held.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 15% on reducing balance Computer equipment - 33% on reducing balance

Taxation

The charity is exempt from corporation tax on its charitable activities.

Fund accounting

Unrestricted funds are available for use at the discretion of the trustees In furtherance of the general objectives of the charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Pension costs and other post-retirement benefits

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Page 11

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2025

2.
OTHER TRADING ACTIVITIES
Commercial exhibition income
Annual conference delegate registration fees
Commission received
Royalties received
Other project income
3.
INVESTMENT INCOME
Deposit account interest
Other interest received
4.
RAISING FUNDS
Raising donations and legacies
Support costs
Other trading activities
Purchases
Awards and prizes
Journal subscriptions
Support costs
Aggregate amounts
5.
SUPPORT COSTS
Management
£
Raising donations and
legacies
117,494
Other trading activities
48,152
165,646		 Finance
£
-
2,468
2,468		 2025
£
256,106
190,641
448
74,000
3,087
524,282
2025
£
7,987
221
8,208
2025
£
117,734
2025
£
364,068
4,186
44,723
56,701
469,678
587,412
Governance
Other
costs
£
£
-
240
801
5,280
801
5,520		 2024
£
225,718
135,015
1,288
75,835
3,286
441,142
2024
£
9,621
-
9,621
2024
£
121,255
2024
£
300,138
2,748
74,029
44,211
421,126
542,381
Totals
£
117,734
56,701
174,435

Page 12

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2025

6. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

Depreciation - owned assets

2025 2024
£ £
801 771

7. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 December 2025 nor for the year ended 31 December 2024.

Trustees' expenses

Payments totalling £2,118 (2024: £2,558) were made to trustees to reimburse travel costs to conferences and council meetings.

8. STAFF COSTS

Wages and salaries
Other pension costs		 2025
£
113,400
4,094
117,494		 2024
£
117,999
3,016
121,015

The average monthly number of employees during the year was as follows:

2025 2024
Administrative 3 3

No employees received emoluments in excess of £60,000.

9.

COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

Unrestricted
fund
£
INCOME AND ENDOWMENTS FROM
Other trading activities
441,142
Investment income
9,414
Other income
75,454
Total
526,010
EXPENDITURE ON
Raising funds
542,381
NET INCOME/(EXPENDITURE)
(16,371)
RECONCILIATION OF FUNDS
Total funds brought forward
481,883
TOTAL FUNDS CARRIED FORWARD
465,512		 Restricted
fund
£
-
207
-
207
-
207
14,273
14,480		 Total
funds
£
441,142
9,621
75,454
526,217
542,381
(16,164)
496,156
479,992

Page 13

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2025

10. TANGIBLE FIXED ASSETS

COST
At 1 January 2025
Additions
At 31 December 2025
DEPRECIATION
At 1 January 2025
Charge for year
At 31 December 2025
NET BOOK VALUE
At 31 December 2025
At 31 December 2024
11.
DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade debtors
Other debtors
VAT
Prepayments and accrued income
12.
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
Trade creditors
Social security and other taxes
VAT
Other creditors
Accrued expenses
13.
MOVEMENT IN FUNDS
Unrestricted funds
General fund
Restricted funds
Ros Breen Fund
TOTAL FUNDS		 Fixtures
and
Computer
fittings
equipment
£
£
905
30,534
-
2,115
905
32,649
746
29,049
24
777
770
29,826
135
2,823
159
1,485
2025
£
78,439
124,913
-
79,987
283,339
2025
£
82,660
2,354
6,574
108,646
4,985
205,219
Net
movement
At 1.1.25
in funds
£
£
465,512
36,932
14,480
162
479,992
37,094		 Totals
£
31,439
2,115
33,554
29,795
801
30,596
2,958
1,644
2024
£
76,022
73,955
10,541
82,505
243,023
2024
£
59,558
2,539
-
116,877
5,702
184,676
At
31.12.25
£
502,444
14,642
517,086

Page 14

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2025

13. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 624,344 (587,412) 36,932
Restricted funds
Ros Breen Fund 162 - 162
TOTAL FUNDS 624,506 (587,412) 37,094
Comparatives for movement in funds
Net
movement At
At 1.1.24 in funds 31.12.24
£ £ £
Unrestricted funds
General fund 481,883 (16,371) 465,512
Restricted funds
Ros Breen Fund 14,273 207 14,480
TOTAL FUNDS 496,156 (16,164) 479,992
Comparative net movement in funds, included in the above are as follows:
Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 526,010 (542,381) (16,371)
Restricted funds
Ros Breen Fund 207 - 207
TOTAL FUNDS 526,217 (542,381) (16,164)
A current year 12 months and prior year 12 months combined position is as follows:
Net
movement At
At 1.1.24 in funds 31.12.25
£ £ £
Unrestricted funds
General fund 481,883 20,561 502,444
Restricted funds
Ros Breen Fund 14,273 369 14,642
TOTAL FUNDS 496,156 20,930 517,086

Page 15

continued...

BRITISH NUCLEAR MEDICINE SOCIETY

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 DECEMBER 2025

13. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 1,150,354 (1,129,793) 20,561
Restricted funds
Ros Breen Fund 369 - 369
TOTAL FUNDS 1,150,723 (1,129,793) 20,930

The Ros Breen Fund was established in memory of Ros Breen, who was Superintendent Radiographer in Nuclear Medicine at Southampton General Hospital. The fund is invested in a capital reserve bank account and the interest earned is then used to provide grants to members of the Technology Group.

14. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 December 2025.

Page 16

BRITISH NUCLEAR MEDICINE SOCIETY

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2025

INCOME AND ENDOWMENTS
Other trading activities
Commercial exhibition income
Annual conference delegate registration fees
Commission received
Royalties received
Other project income
Investment income
Deposit account interest
Other interest received
Other income
Members subscriptions
Total incoming resources
EXPENDITURE
Other trading activities
Scientific meeting expenses
Other project expenses
Awards and prizes
Journal subscriptions
Support costs
Management
Wages and social security
Pensions
Rent
Insurance
Subscriptions
Telephone
Postage and stationery
General meeting and travelling expenses
Sundries
Computer costs
Advertising and website costs
Finance
Bank charges
Card charges
Direct debit processing costs
Other
Fixtures and fittings
Carried forward		 2025
£
256,106
190,641
448
74,000
3,087
524,282
7,987
221
8,208
92,016
624,506
335,241
28,827
4,186
44,723
412,977
113,400
4,094
2,069
1,516
1,961
596
1,250
26,423
81
14,157
99
165,646
1,040
1,428
-
2,468
24
24		 2024
£
225,718
135,015
1,288
75,835
3,286
441,142
9,621
-
9,621
75,454
526,217
295,799
4,339
2,748
74,029
376,915
117,999
3,016
1,312
1,112
2,080
681
658
13,907
247
12,947
-
153,959
1,646
446
1,486
3,578
28
28

This page does not form part of the statutory financial statements

Page 17

BRITISH NUCLEAR MEDICINE SOCIETY

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 DECEMBER 2025

FOR THE YEAR ENDED 31 DECEMBER 2025
2025 2024
£ £
Other
Brought forward 24 28
Computer equipment 777 742
801 770
Governance costs
Independent examiners fees 4,840 5,360
Payroll costs 240 240
Professional fees 440 250
Bookkeeping - 1,309
5,520 7,159
Total resources expended 587,412 542,381
Net income/(expenditure) 37,094 (16,164)

This page does not form part of the statutory financial statements

Page 18